Oral Treatment for Acromegaly Shows Promise
An investigational oral form of octreotide may be beneficial in patients with acromegaly as a maintenance treatment, according to results of the Chiasma OPTIMAL study reported at ENDO 2020, the Endocrine Society’s annual meeting.
In the phase 3 randomized controlled clinical trial, 56 adults with active acromegaly were randomly assigned to receive either octreotide capsules or placebo for 9 months. At the end of treatment, the IGF-1 levels of patients receiving octreotide were on average in the normal range whereas those receiving placebo exceeded normal limits.
The majority of patients (90%) treated with octreotide in the study chose to continue treatment in a longer extension study.
“The results of this study suggest that if oral octreotide capsules are approved by the Food and Drug Administration, this drug has the potential to expand the treatment options for adults with acromegaly beyond injectables,” said the principal investigator Susan Samson, MD, PhD, medical director, Pituitary Center, Baylor St. Luke’s Medical Center in Houston in a press release.
Read the full press release here.